局部晚期非小细胞肺癌同步放化疗的放疗靶区与剂量探索:协作组试验汇总分析
该汇总分析纳入16项协作组同步放化疗试验的3600例局部晚期NSCLC患者个体数据,评估胸部放疗参数对生存的影响。结果显示累及野放疗较选择性淋巴结照射显著改善生存,而总剂量和生物有效剂量与生存无显著关联。
要点
- 累及野放疗较选择性淋巴结照射显著改善总生存。
- 放疗总剂量60 Gy至74 Gy范围内与生存无显著关联。
- 生物有效剂量分组与生存无显著关联。
核心结论
- 对于接受同步放化疗的局部晚期NSCLC患者,累及野放疗较选择性淋巴结照射与显著更好的生存相关。
- 胸部放疗总剂量和生物有效剂量水平与患者生存无显著关联。
研究设计与样本
- 汇总分析16项协作组同步放化疗试验的3600例局部晚期NSCLC患者个体数据。
- 评估的胸部放疗参数包括靶区设计策略(选择性淋巴结照射对比累及野放疗)、总剂量和生物有效剂量。
- 采用单变量和多变量Cox模型计算总生存的风险比。
主要发现
- 选择性淋巴结照射较累及野放疗与更差生存相关(单变量HR=1.37,95%CI:1.24-1.51,p<0.0001;多变量HR=1.31,95%CI:1.08-1.59,p=0.002)。
- 累及野放疗和选择性淋巴结照射患者的中位生存时间分别为24个月和16个月。
- 以低剂量组(60 Gy)为参照,中剂量组(>60 Gy至66 Gy)多变量HR为1.08(95%CI:0.93-1.25),高剂量组(>66 Gy至74 Gy)多变量HR为1.12(95%CI:0.97-1.30);单变量p=0.054,多变量p=0.17。
- 以低BED组(<55.5 Gy10)为参照,中BED组(55.5 Gy10)HR为1.00(95%CI:0.85-1.18),高BED组(>55.5 Gy10)HR为1.10(95%CI:0.93-1.31);单变量p=0.076,多变量p=0.16。
临床怎么用
- 局部晚期NSCLC同步放化疗时应优先采用累及野放疗而非选择性淋巴结照射。
- 在60 Gy至74 Gy范围内,不应仅以提高总剂量或生物有效剂量来追求生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Concurrent chemoradiotherapy (CRT) is standard therapy for locally advanced NSCLC (LA-NSCLC) patients. This study was performed to examine thoracic radiotherapy (TRT) parameters and their impact on patient survival. METHODS: We collected individual patient data from 3600 LA-NSCLC patients participating in 16 cooperative group trials of concurrent CRT. The primary TRT parameters examined included field design strategy (elective nodal irradiation [ENI] compared to involved-field TRT (IF-TRT)), total dose, and biologically effective dose (BED). Hazard ratios (HRs) for overall survival were calculated with univariable and multivariable Cox models. RESULTS: TRT doses ranged from 60 Gy to 74 Gy with most treatments administered once-daily. ENI was associated with poorer survival than IF-TRT (univariable HR = 1.37, 95% confidence interval [CI]: 1.24-1.51, p < 0.0001; multivariable HR = 1.31, 95% CI: 1.08-1.59, p = 0.002). The median survival times of the IF and ENI patients were 24 months and 16 months, respectively. Patients were divided into three dose groups: low total dose (60 Gy), medium total dose (>60 Gy to 66 Gy), and high total dose (>66 Gy to 74 Gy). With reference to the low-dose group, the multivariable HRs were 1.08 for the medium-dose group (95% CI: 0.93-1.25) and 1.12 for the high-dose group (95% CI: 0.97-1.30).The univariate p = 0.054 and multivariable p = 0.17. BED was grouped as follows: low (<55.5 Gy10), medium (55.5 Gy10), or high (>55.5 Gy10). With reference to the low-BED group, the HR was 1.00 (95% CI: 0.85-1.18) for the medium-BED group and 1.10 (95% CI: 0.93-1.31) for the high-BED group. The univariable p = 0.076 and multivariable p = 0.16. CONCLUSIONS: For LA-NSCLC patients treated with concurrent CRT, IF-TRT was associated with significantly better survival than ENI-TRT. TRT total and BED dose levels were not significantly associated with patient survival. Future progress will require research focusing on better systemic therapy and TRT.
引用
- Schild SE, Pang HH, Fan W, et al. Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. J Thorac Oncol. 2018. PMID: 29689435. doi:10.1016/j.jtho.2018.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。